Summary
This 8-K filing from Biogen Inc. reports the final voting results from its 2018 Annual Meeting of Stockholders, held on June 12, 2018. The primary focus for investors is the outcome of key proposals, including the election of directors, ratification of the independent auditor, and executive compensation. All incumbent directors were overwhelmingly re-elected, indicating strong shareholder confidence in the current board's leadership and strategy. Furthermore, the company's selection of PricewaterhouseCoopers LLP as its auditor for fiscal year 2018 was ratified with substantial support. Shareholders also approved the advisory vote on executive compensation, signaling alignment with the company's pay practices. Notably, two shareholder proposals concerning proxy access and drug pricing integration into executive compensation were not approved.
Key Highlights
- 1All eleven director nominees were elected to serve a one-year term until the 2019 annual meeting, receiving a significant majority of votes 'For'.
- 2PricewaterhouseCoopers LLP was ratified as Biogen's independent registered public accounting firm for the fiscal year ending December 31, 2018, with overwhelming support.
- 3The advisory vote on executive compensation was approved by stockholders, reflecting satisfaction with the company's compensation policies.
- 4A stockholder proposal seeking proxy access bylaw amendments was not approved, indicating shareholder preference against these specific changes.
- 5A separate stockholder proposal requesting a report on integrating drug pricing risks into incentive compensation was also not approved.
- 6Director elections saw strong 'For' votes, generally ranging from approximately 153.7 million to 159.7 million, with minimal 'Against' votes.
- 7The ratification of the auditor received over 180 million 'For' votes, demonstrating broad agreement on this matter.